Too much of a good thing? When to stop catch-up vaccination

Medical Decision Making

Volumn 33, Issue 7, 2013, Pages 920-936

  Hutton, David W ^a   Brandeau, Margaret L ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Stanford University   (United States)

Author keywords

epidemic control; hepatitis B; Vaccine

Indexed keywords

HUMAN; IMMUNIZATION; RISK ASSESSMENT; THEORETICAL MODEL; ARTICLE; EPIDEMIC CONTROL; HEPATITIS B;

HUMANS; IMMUNIZATION SCHEDULE; MODELS, THEORETICAL; RISK ASSESSMENT;

VACCINE;

EPIDEMIC CONTROL; HEPATITIS B; VACCINE;

EID: 84884488336     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13493142     Document Type: Article

References (84)

1. World Health Organization. Global Health Immunization Vision and Strategy 2006-2015. 2005 [cited November 12, 2008]. Available from: http://www.who.int/ vaccines-documents/DocsPDF05/GIVS-Final-EN.pdf
2. 3 rd ed.Geneva, Switzerland: World Health Organization; 2009. Geneva, Switzerland: World Health Organization ; 2009 :
3. World Health Organization. Fact sheet no. 288: immunization against diseases of public health importance. 2005 [cited May 2, 2011]. Available from: http://libdoc.who.int/fact-sheet/2005/FS-288.pdf
4. MMWR Morb Mortal Wkly Rep.. 2007 ; 56 (18). 441-5
5. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med. 2007 ; 356 (19). 1908-10
6. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994 ; 271 (5). 375-81
7. Lieu TTA, Ray GGT, Black SSB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000 ; 283 (11). 1460-8
8. Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine. 2000 ; 18: S35-8
9. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ. 2000 ; 9 (1). 19-35
10. Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010 ; 51 (2). 405-14
11. Hersh BS, Tambini G, Nogueira AC, Carrasco P, de Quadros CA. Review of regional measles surveillance data in the Americas, 1996-99. Lancet. 2000 ; 355 (9219). 1943-8
12. Biellik R, Madema S, Taole A, et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet. 2002 ; 359 (9317). 1564-8
13. Levine R Sudbury, MA: Jones and Bartlett; ; 2007 :
14. World Health Organization. The global polio eradication initiative. 2008 [cited November 12, 2008]. Available from: http://www.who.int/mediacentre/ events/2006/g8summit/polio/en/
15. Clements CJ, Baoping Y, Crouch A, et al. Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine. 2006 ; 24 (12). 1975-82
16. Lu C, Michaud CM, Gakidou E, Khan K, Murray CJ. Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment. Lancet. 2006 ; 368 (9541). 1088-95
17. Wickwire K. Optimal immunization rules for an epidemic with recovery. J Optimiz Theory Applic. 1979 ; 27 (4). 549-70
18. Gold MR, Siegel JE, Russell LB, Weinstein MC Oxford, UK: Oxford University Press ; 1996 :
19. Huang SZ. A new SEIR epidemic model with applications to the theory of eradication and control of diseases, and to the calculation of R0. Math Biosci. 2008 ; 215 (1). 84-104
20. Ball F, Britton T, Lyne O. Stochastic multitype epidemics in a community of households: estimation and form of optimal vaccination schemes. Math Biosci. 2004 ; 19 (1). 19-40
21. May RM, Anderson RM. Spatial heterogeneity and the design of immunization programs. Math Biosci. 1984 ; 72: 83-111
22. Anderson RM, May RM Oxford, UK: Oxford University Press ; 1991 :
23. Tanner MW, Sattenspiel L, Ntaimo L. Finding optimal vaccination strategies under parameter uncertainty using stochastic programming. Math Biosci. 2008 ; 215: 144-51
24. Anderson RM, May RM. Spatial, temporal, and genetic heterogeneity in host populations and the design of immunisation programs. IMA J Math Appl Med Biol. 1984 ; 1: 233-66
25. Tennenbaum S. Simple criteria for finding (nearly) optimal vaccination strategies. J Theor Biol. 2008 ; 250 (4). 673-83
26. Matrajt L, Longini IM. Critical immune and vaccination thresholds for determining multiple influenza epidemic waves. Epidemics. 2012 ; 4 (1). 22-32
27. Carrat F, Pelat C, Levy-Bruhl D, Bonmarin I, Lapidus N. Planning for the next influenza H1N1 season: a modelling study. BMC Infect Dis. 2010 ; 10: 301
28. Zhao S, Xu Z, Lu Y. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China. Int J Epidemiol. 2000 ; 29 (4). 744-52
29. Hens N, Aerts M, Shkedy Z, et al. Estimating the impact of vaccination using age-time-dependent incidence rates of hepatitis B. Epidemiol Infect. 2008 ; 136 (3). 341-51
30. Zou L, Zhang W, Ruan S. Modeling the transmission dynamics and control of hepatitis B virus in China. J Theor Biol. 2010 ; 262 (2). 330-8
31. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998 ; 279 (17). 1371-6
32. Lee GM, Murphy TV, Lett S, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007 ; 32 (3). 186-93
33. Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005 ; 115 (5). 1220-32
34. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003 ; 290 (6). 781-9
35. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004 ; 96 (8). 604-15
36. Krahn MD, John-Baptiste A, Yi Q, et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine. 2005 ; 23 (13). 1549-58
37. Bauch CT, Anonychuk AM, Effelterre TV, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making. 2009 ; 29 (5). 557-69
38. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999 ; 18: 3263-82
39. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003 ; 23 (1). 76-82
40. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005 ; 191: S97-106
41. Centers for Disease Control and Prevention. Recommendations and guidelines: 2009 child & adolescent immunization schedules. 2009 [cited October 26, 2009]. Available from: http://www.cdc.gov/vaccines/recs/schedules/ child-schedule.htm
42. Abakuks A. Optimal immunisation policies for epidemics. Adv Appl Prob. 1974 ; 6 (3). 494-511
43. Muller J. Optimal vaccination patterns in age-structured populations. SIAM J Appl Math. 1998 ; 59 (1). 222-41
44. World Health Organization. Fact sheet no. 204: hepatitis B. 2008 [cited October 29, 2009]. Available from: http://www.who.int/mediacentre/factsheets/ fs204/en/
45. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW 3 rd ed.Oxford, UK: Oxford University Press; 2005. Oxford, UK: Oxford University Press ; 2005 :
46. Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population Health. Annu Rev Public Health. 2002 ; 23: 115-34
47. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006 ; 21 (5). 402-8
48. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000 ; 9 (3). 235-51
49. Geneva, Switzerland: World Health Organization ; 2001 :
50. Johns B, Torres TT. Costs of scaling up health interventions: a systematic review. Health Policy Plan. 2005 ; 20 (1). 1-13
51. Wang L, Li J, Chen H, et al. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull World Health Organ. 2007 ; 85 (9). 688-94
52. Schelling E, Bechir M, Ahmed MA, Wyss K, Randolph TF, Zinsstag J. Human and animal vaccination delivery to remote nomadic families, Chad. Emerg Infect Dis. 2007 ; 13 (3). 373-9
53. Brenzel L, Claquin P. Immunization programs and their costs. Soc Sci Med. 1994 ; 39 (4). 527-36
54. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007 ; 147 (7). 460-9
55. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996 ; 117 (2). 313-25
56. Liu J, Fan D. Hepatitis B in China. Lancet. 2007 ; 369 (9573). 1582-3
57. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000 ; 61 (3). 362-6
58. Chinese Ministry of Health. The Ministry of Health conference on planning and hepatitis B immunization, malaria prevention and control work [in Chinese]. 2008 [cited August 1, 2009]. Available from: http://www.gov.cn/xwfb/2008-04/21/ content-950425.htm
59. Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. MMWR Morb Mortal Wkly Rep. 2007 ; 56 (18). 441-5
60. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993 ; 253 (1337). 197-201
61. Centers for Disease Control and Prevention. Hepatitis B fact sheet. 2010 [cited May 2, 2011]. Available from: http://www.cdc.gov/hepatitis/HBV/PDFs/ HepBGeneralFactSheet-BW.pdf
62. Manila, Philippines: World Health Organization ; 2007 :
63. Chen JJ. A model HBV catch-up immunization and education project in Qinghai, China. Paper presented at the National Immunization Conference; ; Atlanta, GA ;..
64. Kretzschmar M, de Wit GA, Smits LJ, van de, Laar MJ. Vaccination against hepatitis B in low endemic countries. Epidemiol Infect. 2002 ; 128 (2). 229-44
65. Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 ; 116 (1). 71-89
66. International Monetary Fund. World Economic Outlook Database October 2007 Edition. 2007 [cited August 1, 2009]. Available from: http://www.imf.org/ external/pubs/ft/weo/2007/02/weodata/index.aspx
67. World Bank. World Development Indicators Database. 2007 [cited August 1, 2008]. Available from: http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/ 0,contentMDK:20394822∼isCURL:Y∼menuPK:1192694∼pagePK: 64133150∼piPK:64133175∼theSitePK:239419,00.html
68. Central Intelligence Agency. The World Factbook - China. 2008 [cited August 1, 2009]. Available from: https://www.cia.gov/library/publications/the- world-factbook/geos/ch.html#Econ
69. European Consensus Group on Hepatitis B Immunity. Lancet. 2000 ; 355 (9203). 561-5
70. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009 ; 200 (9). 1390-6
71. World Health Organization. WHO Disease and Injury Country Estimates. 2004 [cited October 30, 2009]. Available from: http://www.who.int/healthinfo/global- burden-disease/estimates-country/en/index.html
72. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005 ; 436 (7053). 961-6
73. Ledford H. HIV vaccine developers battle on, despite high-profile failures. Nat Biotechnol. 2008 ; 26 (6). 591-2
74. UNICEF. 2003Vaccine Projection: Quantities and Pricing [cited November 18, 2008]. Available from: http://www.unicef.org/supply/files/2003-Vaccine- Projection.pdf
75. Zhiqiang G, Zhaohui D, Qinhuan W, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol. 2004 ; 38: S175-8
76. Chen D, Yao G-B, Chen W. Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B [in Chinese]. Chin Hepatol. 2007 ; 12 (3). 164-7
77. Li SC, Ong SC, Lim SG, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol. 2004 ; 38: S136-43
78. Lacey L, Tan A. Economic evaluation of different treatments of HBeAg-negative chronic hepatitis B in China [in Chinese]. Chin J Infect Dis. 2007 ; 25 (8). 473-9
79. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a Cost-effectiveness analysis. Ann Intern Med. 2005 ; 142 (10). 821-31
80. Jacobs R, Saab S, Meyerhoff A. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health. 2003 ; 51: 227-36
81. Shivananda Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin Vaccine Immunol. 2006 ; 13 (6). 661-4
82. Alimonos KK, Nafziger AAN, Murray JJ, Bertino JJS. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?. Clin Infect Dis. 1998 ; 26 (3). 566-71
83. Bristol-MyersSquibb. Bristol-Myers Squibb Foundation and China Foundation for Hepatitis Prevention and Control collaborate to fight one of China's most pressing health problems. 2004 [cited November 1, 2008]. Available from: http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-newsArticle&ID= 638504&highlight=
84. HoL. Public 'lacks awareness' of hepatitis B. 2007 [cited November 1, 2008]. Available from: http://www.chinadaily.com.cn/cndy/2007-12/11/content- 6311290.htm